7S6I

SARS-CoV-2-6P-Mut2 S protein

7S6I の概要

• エントリーDOI: 10.2210/pdb7s6i/pdb
• EMDBエントリー: 24876
• 分子名称: Spike glycoprotein, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total)
• 機能のキーワード: covid, sars, cov-2, viral glycoprotein, spike, stabilizing mutations, coronavirus, viral protein, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2)
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 438254.72

構造登録者

Ozorowski, G.,Torres, J.L.,Ward, A.B. (登録日: 2021-09-14, 公開日: 2022-05-11, 最終更新日: 2025-05-21)

主引用文献

Torres, J.L.,Ozorowski, G.,Andreano, E.,Liu, H.,Copps, J.,Piccini, G.,Donnici, L.,Conti, M.,Planchais, C.,Planas, D.,Manganaro, N.,Pantano, E.,Paciello, I.,Pileri, P.,Bruel, T.,Montomoli, E.,Mouquet, H.,Schwartz, O.,Sala, C.,De Francesco, R.,Wilson, I.A.,Rappuoli, R.,Ward, A.B.
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody.
Proc.Natl.Acad.Sci.USA, 119:e2120976119-e2120976119, 2022

PubMed Abstract: As the coronavirus disease 2019 (COVID-19) pandemic continues, there is a strong need for highly potent monoclonal antibodies (mAbs) that are resistant against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoCs). Here, we evaluate the potency of the previously described mAb J08 against these variants using cell-based assays and delve into the molecular details of the binding interaction using cryoelectron microscopy (cryo-EM) and X-ray crystallography. We show that mAb J08 has low nanomolar affinity against most VoCs and binds high on the receptor binding domain (RBD) ridge, away from many VoC mutations. These findings further validate the phase II/III human clinical trial underway using mAb J08 as a monoclonal therapy.

PubMed: 35549549
DOI: 10.1073/pnas.2120976119

実験手法

ELECTRON MICROSCOPY (3.2 Å)